BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gatti M, De Ponti F. Drug Repurposing in the COVID-19 Era: Insights from Case Studies Showing Pharmaceutical Peculiarities. Pharmaceutics 2021;13:302. [PMID: 33668969 DOI: 10.3390/pharmaceutics13030302] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Prathapan P. A determination of pan-pathogen antimicrobials? Medicine in Drug Discovery 2022. [DOI: 10.1016/j.medidd.2022.100120] [Reference Citation Analysis]
2 Sukmarini L. Antiviral Peptides (AVPs) of Marine Origin as Propitious Therapeutic Drug Candidates for the Treatment of Human Viruses. Molecules 2022;27:2619. [PMID: 35565968 DOI: 10.3390/molecules27092619] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Besaratinia A, Caliri AW, Tommasi S. Hydroxychloroquine induces oxidative DNA damage and mutation in mammalian cells. DNA Repair (Amst) 2021;106:103180. [PMID: 34298488 DOI: 10.1016/j.dnarep.2021.103180] [Reference Citation Analysis]
4 de-Oliveira-Pinto LM, Fiestas Solórzano VE, de Lourdes Martins M, Fernandes-Santos C, Damasco PH, de Siqueira MAMT, Dias HG, Pauvolid-Corrêa A, Damasco PV, de Azeredo EL. Comparative Analysis of Circulating Levels of SARS-CoV-2 Antibodies and Inflammatory Mediators in Healthcare Workers and COVID-19 Patients. Viruses 2022;14:455. [PMID: 35336861 DOI: 10.3390/v14030455] [Reference Citation Analysis]
5 Albariqi AH, Wang Y, Yoon Kyung Chang R, Quan DH, Wang X, Kalfas S, Drago J, Britton WJ, Chan HK. Pharmacokinetics and Safety of Inhaled Ivermectin in Mice as a Potential COVID-19 Treatment. Int J Pharm 2022;:121688. [PMID: 35314278 DOI: 10.1016/j.ijpharm.2022.121688] [Reference Citation Analysis]
6 Shin YS, Lee JY, Jeon S, Cho J, Myung S, Jang MS, Kim S, Song JH, Kim HR, Park H, Jeong LS, Park CM. Optimization of 2-Aminoquinazolin-4-(3H)-one Derivatives as Potent Inhibitors of SARS-CoV-2: Improved Synthesis and Pharmacokinetic Properties. Pharmaceuticals 2022;15:831. [DOI: 10.3390/ph15070831] [Reference Citation Analysis]
7 Gatti M, Turrini E, Raschi E, Sestili P, Fimognari C. Janus Kinase Inhibitors and Coronavirus Disease (COVID)-19: Rationale, Clinical Evidence and Safety Issues. Pharmaceuticals (Basel) 2021;14:738. [PMID: 34451835 DOI: 10.3390/ph14080738] [Cited by in Crossref: 6] [Article Influence: 6.0] [Reference Citation Analysis]
8 Mignani S, Shi X, Karpus A, Lentini G, Majoral JP. Functionalized Dendrimer Platforms as a New Forefront Arsenal Targeting SARS-CoV-2: An Opportunity. Pharmaceutics 2021;13:1513. [PMID: 34575589 DOI: 10.3390/pharmaceutics13091513] [Reference Citation Analysis]
9 Paiardi G, Richter S, Oreste P, Urbinati C, Rusnati M, Wade RC. The binding of heparin to spike glycoprotein inhibits SARS-CoV-2 infection by three mechanisms. J Biol Chem 2021;:101507. [PMID: 34929169 DOI: 10.1016/j.jbc.2021.101507] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 15.0] [Reference Citation Analysis]
10 Pasqua E, Hamblin N, Edwards C, Baker-Glenn C, Hurley C. Developing inhaled drugs for respiratory diseases: A medicinal chemistry perspective. Drug Discov Today 2021:S1359-6446(21)00394-9. [PMID: 34547449 DOI: 10.1016/j.drudis.2021.09.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
11 Jukič M, Kores K, Janežič D, Bren U. Repurposing of Drugs for SARS-CoV-2 Using Inverse Docking Fingerprints. Front Chem 2021;9:757826. [PMID: 35028304 DOI: 10.3389/fchem.2021.757826] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]